This might be bad news. Many here, me included, thought PFE was logical buyer of $ESPR. PFE already owns big stake in ESPR and it owns Lipitor, the best selling statin ever. But maybe both are wrong. 1. This website shows PFE owns 4.8% of ESPR based on a 2015 filing. Today we learned (I think) that Longitude is also shown as an 11% owner of ESPR based on a 2015 filing. But Longitude site says they exited, so is everything from 2015 is wrong? fintel.io/so/us/espr 2. The footer on lipitor.com/ website shows it is now owned by Viatris $VTRS, the PFE spinoff. In November PFE sent its Upjohn unit VTRS. "The Upjohn Business ... includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica, Lipitor, Celebrex and Viagra." seekingalpha.com/filing/522... PFE website shows it still owns Lipitor, but that's probably wrong: pfizer.com/products-list If PFE no longer has Lipitor, why would it want ESPR? Maybe VTRS wants it?
9
1
@Gary9912 @superdex75 OK, so MRK it is. But the hope was that someone else would get in bidding war with MRK. PFE made sense because of the deep history it had with ESPR. Maybe VTRS is interested in doing something that would generate growth? VTRS has been spurned as a depressing new company to manage a bunch of dying old drugs. If VRTS could so something to give new growth to one of these dying drugs, its management team might earn some respect. It is a $22B company so it can afford ESPR. Not as easily as the $190B PFE and MRK could have, but it would be a big bold move for VTRS.
1